Sobi to retain Partner Products business area

Nordic drugmaker Swedish Orphan Biovitrum (STO: SOBI) now says that the Partner Products business area will remain an integral part of Sobi’s business model for the purpose of creating value when taking the company to the next level.

Thereby, discussions regarding a potential sale of the Partner Products business area, which Sobi confirmed were ongoing in a press release in February 2017, have been terminated. Sobi will continue to build on the results of the growing hemophilia business and create value through its other rare disease portfolios in the years to come.

“Our Partner Products portfolio is a valuable rare disease platform in Sobi’s business today. We have assessed the options to potentially divest the portfolio, and the conclusion is that going forward this interesting business element will continue to serve as an integral part of Sobi, giving us access to new earnings streams, and supporting both our commercial footprint and attractiveness as a business partner in Europe, the Middle East, North Africa and North America,” says Guido Oelkers, the firm’s chief executive and president, who took on the post after the departure in May of Geoffrey McDonough, who announced Sobi’s original decision to consider the sales of the Partner Products business.